Cargando…

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results

BACKGROUND: The introduction of biologics has revolutionized the management of the chronic inflammatory bowel disease, ulcerative colitis (UC), with many patients experiencing significant improvements not only in their symptoms but in other outcomes relevant to individuals and society as a whole. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teich, Niels, Grümmer, Harald, Jörgensen, Eric, Liceni, Thomas, Holtkamp-Endemann, Frank, Fischer, Tim, Hohenberger, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284175/ https://www.ncbi.nlm.nih.gov/pubmed/32550760 http://dx.doi.org/10.3748/wjg.v26.i21.2852

Ejemplares similares

Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months
por: Teich, Niels, et al.
Publicado: (2021)

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study
por: Bosca-Watts, Marta Maia, et al.
Publicado: (2016)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Golimumab for the treatment of ulcerative colitis
por: Flamant, Mathurin, et al.
Publicado: (2017)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Low Occurrence of Colectomy With Long-Term (up to 4 Years) Golimumab Treatment in Patients With Moderate-to-Severe Active Ulcerative Colitis: Data From the PURSUIT Maintenance and Long-Term Extension Studies
por: Weinstein, Cindy L J, et al.
Publicado: (2023)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003–2016
por: Vadstrup, Kasper, et al.
Publicado: (2020)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
por: Iborra, Marisa, et al.
Publicado: (2020)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis
por: Kinoshita, Naohiko, et al.
Publicado: (2022)

Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis
por: Kerur, Basavaraj, et al.
Publicado: (2017)

Medical Therapy of Active Ulcerative Colitis
por: Bürger, Martin, et al.
Publicado: (2015)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
por: Perrig, Kathrin, et al.
Publicado: (2022)

Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis
por: Klepp, Pasquale, et al.
Publicado: (2018)

Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
por: Bessissow, Talat, et al.
Publicado: (2022)

Inflammatory Response in Patients With Crohn’s Disease Compared With Ulcerative Colitis: Secondary Results of a Prospective Pilot Study
por: El-Hussuna, Alaa, et al.
Publicado: (2022)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Golimumab for the Prediction of Long-Term Clinical Remission in Patients with Ulcerative Colitis
por: Tawa, Hideki, et al.
Publicado: (2022)

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis
por: Zhao, Hong-Ying, et al.
Publicado: (2017)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Clinical course of ulcerative colitis patients who develop acute pancreatitis
por: Kim, Jong Wook, et al.
Publicado: (2017)

Outcomes of a drug shortage requiring switching in patients with ulcerative colitis
por: van Langenberg, Daniel R, et al.
Publicado: (2020)

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis
por: Rutgeerts, P., et al.
Publicado: (2015)

Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis
por: He, Xu-Xia, et al.
Publicado: (2021)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan
por: Itabashi, Michio, et al.
Publicado: (2021)

Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
por: Sharma, Shreyak, et al.
Publicado: (2023)

Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results
por: Hyams, Jeffrey S, et al.
Publicado: (2020)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
por: Hoque, Sami, et al.
Publicado: (2020)

Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report
por: Alhalabi, Marouf M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g05647fq7eh7q6efognnkrh535